Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/10045
Title: | A phase 1 and pharmacokinetic study of gemcitabine and oxaliplatin in patients with solid tumors. | Austin Authors: | Gan, Hui K ;Mitchell, Paul L R ;Galettis, Peter;Davis, Ian D;Cebon, Jonathan S ;de Souza, Paul;Links, Matthew | Affiliation: | huikg@bigpond.net.au Department of Medical Oncology and Ludwig Institute for Cancer Research, Austin Hospital, Heidelberg, Melbourne, Victoria, Australia |
Issue Date: | 19-Nov-2005 | Publication information: | Cancer Chemotherapy and Pharmacology 2005; 58(2): 157-64 | Abstract: | This dose escalation study aimed to determine the recommended doses, toxicity and pharmacokinetics of oxaliplatin and gemcitabine given on days 1 and 8 every 21 days. This schedule may maximize dose intensity of both drugs with acceptable or reduced toxicity.Eligible patients had solid malignancies, no more than two prior courses of chemotherapy, ECOG performance status 0-2, neurotoxicity < or = NCI-CTC grade 1 and adequate organ function. Dose escalation commenced at oxaliplatin 40 mg/m(2) and gemcitabine 750 mg/m(2), both given on days 1 and 8 every 21 days, and reached oxaliplatin 80 mg/m(2) and gemcitabine 1,500 mg/m(2). The two highest dose levels were each expanded to six patients to gain additional toxicity data.There were no dose limiting toxicities related to treatment and an MTD was not reached. Five patients (24%) had grade 3 neutropenia, without associated infection, and seven patients (33%) had grade 3/4 thrombocytopenia. Neurotoxicity was mild and no worse than grade 1. Two patients with mesothelioma (10%) had partial responses and 11 patients (52%) had disease stabilization. No pharmacokinetic interaction between oxaliplatin and gemcitabine was detected. Dose intensity was maximal at level 4 (oxaliplatin 70 mg/m(2) and gemcitabine 1,250 mg/m(2)).This schedule allows oxaliplatin and gemcitabine to be delivered at the full dose intensity of each drug with excellent tolerability and predictable pharmacokinetics. The recommended doses for phase II studies are oxaliplatin 70 mg/m(2) and gemcitabine 1,250 mg/m(2) on days 1 and 8 every 21 days. | Gov't Doc #: | 16328413 | URI: | https://ahro.austin.org.au/austinjspui/handle/1/10045 | DOI: | 10.1007/s00280-005-0152-y | Journal: | Cancer chemotherapy and pharmacology | URL: | https://pubmed.ncbi.nlm.nih.gov/16328413 | Type: | Journal Article | Subjects: | Adult Aged Antineoplastic Combined Chemotherapy Protocols.adverse effects.pharmacokinetics.therapeutic use Area Under Curve Deoxycytidine.administration & dosage.analogs & derivatives Female Humans Male Middle Aged Neoplasms.drug therapy.metabolism Organoplatinum Compounds.administration & dosage |
Appears in Collections: | Journal articles |
Files in This Item:
File | Size | Format | |
---|---|---|---|
16328413.pdf | 60.12 kB | Adobe PDF | View/Open |
Page view(s)
32
checked on Aug 29, 2024
Download(s)
84
checked on Aug 29, 2024
Google ScholarTM
Check
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.